Utilizing virus genomic surveillance to predict vaccine effectiveness
PLOS Computational Biology · 26.05.2026 · 22 (5) · e1014329
DOI: 10.1371/journal.pcbi.1014329 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, online erschienen am 26.05.2026. Verfasst von Jiye Kwon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19 Vaccines, Vaccine Efficacy, Genome, Viral. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Since the development of the first vaccines targeting the original SARS-CoV-2 virus sequence in 2020, mRNA-based vaccines have been updated three times: targeting Omicron BA.4/BA.5 in 2022, the XBB lineage in 2023, and the KP.2 variant in 2024. While genomic surveillance has advanced our understanding of pathogen diversity, gaps remain in incorporating genomic information to evaluate vaccine effectiveness (VE) against emerging variants. This study aims to characterize the relationship between VE and sequence-based genetic distance, to establish a framework for predicting near real-time changes in the level of vaccine protection from virus surveillance data.
Methods
We analyzed 10,156 whole genome sequences of SARS-CoV-2 cases from Connecticut, USA, between April 2021 to July 2024. We first assessed how genetic distance, specifically the number of amino acid substitutions in the spike gene between COVID-19 case sequences and the mRNA vaccine formulation sequence(s), correlates with vaccine protection levels. Incorporating data from over 1 million test-negative controls, we developed a Bayesian time-varying model with autoregressive terms to assess VE at a weekly level. The analysis was adjusted for ZIP-code-level income, age, sex, and prior vaccine doses received. We then employed a random effects meta-regression to explore the relationship between VE and amino acid distance over time. Finally, we used the meta-regression model to estimate potential vaccine protection against emerging variants.
Findings
We found that spike gene amino acid distance showed a negative correlation with VE over time. Stepwise increases in amino acid distance aligned with sharp VE declines during variant emergence, while accumulation of within-variant changes was also associated with gradual VE decline. Each 10 amino acid increase in distance in the spike gene corresponds to a predicted 15.4% (95% credible intervals (CrI): –2.0%, 34.6%) reduction in VE. For the 2023/24 updated vaccine, spike distance rose from 12.25 to 30.23, predicting a 43.4% (95% CrI: –5.7%, 90.1%) drop in VE using sequence information alone.
Conclusion
Our framework quantifies how the emergence of new variants is expected to affect VE for SARS-CoV-2. By quantifying the relationship between amino acid substitutions and time-varying VE, we leverage intrinsic pathogen features, such as spike amino acid distance, to inform future vaccine updates using genomic sequences. As genomic surveillance data becomes more widely available across pathogens, this framework can serve as a near-real time surveillance tool to infer population-level protection and offers valuable insights for vaccine update decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
- Public Health Modeling Unit, Yale School of Public Health, New Haven, Connecticut, United States of America.
- Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, United States of America.
- Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
- Yale School of Medicine Biorepository, Yale University, New Haven, Connecticut, United States of America.
- Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
ORCID-Profile: Jiye Kwon, Joshua L Warren, Anne M Hahn
Förderung
- Centers for Disease Control and Prevention
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Kwon, J., Li, K., Warren, J. L., Pandya, S., Hahn, A. M., Yale SARS-CoV-2 Genomic Surveillance Initiative, Pitzer, V. E., Weinberger, D. M., & Grubaugh, N. D. (2026). Utilizing virus genomic surveillance to predict vaccine effectiveness. PLOS Computational Biology, 22(5), e1014329. https://doi.org/10.1371/journal.pcbi.1014329
Vancouver
Kwon J, Li K, Warren JL, Pandya S, Hahn AM, Yale SARS-CoV-2 Genomic Surveillance Initiative, et al. Utilizing virus genomic surveillance to predict vaccine effectiveness. PLOS Computational Biology. 2026;22(5):e1014329. doi:10.1371/journal.pcbi.1014329
BibTeX
@article{Kwon2026,
author = {Kwon, Jiye and Li, Ke and Warren, Joshua L and Pandya, Sameer and Hahn, Anne M and Yale SARS-CoV-2 Genomic Surveillance Initiative, Yale SARS-CoV-2 Genomic Surveillance Initiative and Pitzer, Virginia E and Weinberger, Daniel M and Grubaugh, Nathan D},
title = {Utilizing virus genomic surveillance to predict vaccine effectiveness},
journal = {PLOS Computational Biology},
year = {2026},
volume = {22},
number = {5},
pages = {e1014329},
doi = {10.1371/journal.pcbi.1014329}
}
EUVIMED